Why the study?
Does andexanet alfa reverse the effects of factor Xa inhibitors in patients with life-threatening or uncontrolled bleeding?
Does andexanet alfa reverse the effects of factor Xa inhibitors in patients with life-threatening or uncontrolled bleeding?
Andexanet alfa is an effective reversal agent for apixaban and rivaroxaban in life-threatening bleeding, but well-designed comparative studies are still needed.
Answers are grounded in this paper and cite their sources.
May support andexanet alfa for factor Xa inhibitor bleeding; leaves open need for randomized comparisons.
INTRODUCTION: Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa inhibitors. Since May 2018, the FDA has approved its utilization in patients treated with apixaban and rivaroxaban in case of life-threatening or uncontrolled bleeding. On 28 of February 2019, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a conditional marketing authorization for andexanet alfa in Europe. Area covered: The authors provide an overview of andexanet alfa development and its pharmacokinetic and pharmacodynamic properties. The results of the clinical phase III trial ANNEXA as well as current limitations related to andexanet alfa are also discussed. Expert opinion: Although phase I and II studies have proven that andexanet alfa can be effective in reversing the effect of factor Xa inhibitors, its efficacy in major bleeding patients has only been shown for apixaban and rivaroxaban, without any comparator group. Well-designed studies comparing the efficacy and safety of andexanet alfa to other reversal strategies are required to confirm preliminary data. The benefit of andexanet alfa in specific settings needs to be investigated and its use in clinical practice needs to be facilitated by the implementation of international guidelines.
No takes yet. Share an insight, caveat, or question.
Favresse et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: